# US 2026/0242330 A1 · Use of an amantadine mononitrate compound in manufacture of a medicament for the prevention and treatment of hypertension

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242330 A1
- Document ID: US20260242330A1
- Status: Published application
- Kind: A1
- Application number: 18/831,145
- Filed: 2023-02-24
- Published: 2026-08-20
- Earliest claimed: 2022-03-01
- Assignees: Guangzhou Magpie Pharmaceuticals Co., Ltd.
- Applicants: Guangzhou Magpie Pharmaceuticals Co., Ltd.
- Inventors: Yuqiang WANG; Yewei SUN; Gaoxiao ZHANG; Zaijun ZHANG; Peng YI
- Web page: https://patentgrep.com/patent/US20260242330A1

## CPC

- C07C 211/38: containing condensed ring systems
- A61K 31/133: having hydroxy groups, e.g. sphingosine
- A61K 31/21: Esters, e.g. nitroglycerine, selenocyanates
- A61P 9/12: Antihypertensives
- C07C 2603/74: Adamantanes
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides the use of an amantadine mononitrate compound in the manufacture of a medicament for the prevention and treatment of hypertension. The amantadine mononitrate compound can be administered to reduce the systolic and/or diastolic pressure of subjects. The amantadine mononitrate compound has a long half-life and long drug action time in subjects and can reduce the number of administration times and improve patient compliance as compared to existing hypertensive drugs. The medicament of the amantadine mononitrate compound of the present invention has no adverse reactions of orthostatic hypotension, and thus has improved the safety of the drug use.

## Claims

### Claim 1

Use of an amantadine mononitrate compound and a pharmaceutically acceptable salt thereof in manufacture of a medicament, wherein the medicament comprising the amantadine mononitrate compound or a pharmaceutically acceptable salt thereof for the prevention and treatment of hypertension; wherein the hypertension is hypertension with high diastolic pressure; and wherein the amantadine mononitrate compound has a structure of formula (I):
wherein, R is a straight-chain or branched-chain alkyl, and n is 1-6.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The use of claim 1, wherein the amantadine mononitrate compound has a formula below:

### Claim 4 (depends on 4)

The use of claim 4, wherein the amino amantadine mononitrate compound is MN-08 having the following formula:

### Claim 5 (depends on 1)

The use of claim 1, wherein the pharmaceutically acceptable salt is a salt formed by the amino amantadine mononitrate compound and an acid; wherein the acid is selected from: hydrochloric acid (HCl), hydrobromic acid (HBr), hydroiodic acid, sulfuric acid, pyrosulfuric acid, phosphoric acid, nitric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, formic acid, acetic acid, acetoacetic acid, pyruvic acid, trifluoroacetic acid, propionic acid, butyric acid, hexanoic acid, heptanoic acid, undecanoic acid, Lauric acid, benzoic acid, salicylic acid, 2-(4-hydroxybenzoyl) benzoic acid, camphoric acid, cinnamic acid, cyclopentanepropanoic acid, digluconic acid, 3-hydroxy-2-naphthoic acid, nicotinic acid, pamoic acid, pectinic acid, persulfuric acid, 3-phenylpropanoic acid, picric acid, terpene acid, 2-hydroxyethanesulfonic acid, itaconic acid, amino sulfonic acid, trifluoromethanesulfonic acid, dodecyl sulfuric acid, 2-naphthalene sulfonic acid, naphthalene disulfonic acid, camphor sulfonic acid, citric acid, tartaric acid Stearic acid, lactic acid, oxalic acid, malonic acid, succinic acid, malic acid, fatty acid, algic acid, maleic acid, fumaric acid, D-gluconic acid, mandelic acid, ascorbic acid, glucoheptanoic acid, glycerol phosphate, aspartic acid, sulfosalicylic acid, hemisulfuric acid, thiocyanic acid, 1,2-ethanedisulfonic acid, ethanolic acid, p-chlorobenzenesulfonic acid, trimethylacetic acid, tert-butyl acetic acid, hydroxynaphthalic acid, or glutamic acid.

### Claim 6 (depends on 1)

The use of claim 1, wherein the diastolic pressure is ≥80 mmHg.

### Claim 7 (depends on 6)

The use of claim 6, wherein the diastolic pressure is 80 to 89 mmHg.

### Claim 8 (depends on 7)

The use of claim 7, wherein the diastolic pressure is 90 to 99 mmHg.

### Claim 9 (depends on 6)

The use of claim 6, wherein the diastolic pressure is 100 to 109 mmHg.

### Claim 10 (depends on 6)

The use of claim 6, wherein the diastolic pressure is ≥110 mmHg.

### Claim 11 (depends on 1)

The use of claim 1, wherein the medicament further comprises a pharmaceutically acceptable carrier.
